PITRM1 and Alzheimer disease: Furthermore, reduced hPreP levels were reported in AD patient brains compared to control; thus, clearance of Aβ via hPreP can be explored as a therapeutic option (Alikhani et al., 2011; Teixeira et al., 2012).